(Gabriele D’Annunzio, Il piacere)

Usage in computer system menus
In computer menu functions or buttons, an ellipsis means that upon selection more options (sometimes in the form of a dialog box) will be displayed, where the user can or must make a choice. If the ellipsis is absent, the function is immediately executed upon selection. For example, the menu item "Save" indicates that the file will be overwritten without further input, whereas "Save as..." indicates that a dialog follows where the user can, for example, select another location, file name, or format. Ellipses are also used as a separate button (particularly considering the limited screen area of mobile apps) to represent partially or completely hidden options. This usage may alternatively be described as a "More button" (see also hamburger button signifying completely hidden options). In mobile, web, and general application design, the vertical ellipsis, ⋮, is sometimes used as an interface element, where it is sometimes called a kebab icon. The element typically indicates that a navigation menu can be accessed when the element is activated, and is a smaller version of the hamburger icon (≡) which is a stylized rendering of a menu. In mathematical notation
An ellipsis is also often used in mathematics to mean "and so forth".
Protein-bound paclitaxel, also known as nanoparticle albumin–bound paclitaxel or  nab-paclitaxel, is an injectable formulation of paclitaxel used to treat breast cancer, lung cancer and pancreatic cancer, among others. Paclitaxel kills cancer cells by preventing the normal breakdown of microtubules during cell division. In this formulation, paclitaxel is bonded to albumin as a delivery vehicle. It is manufactured and sold in the United States by Celgene under the trade name Abraxane where it is designated as an orphan drug as first-line treatment, in combination with gemcitabine, for the orphan disease "metastatic adenocarcinoma of the pancreas".This treatment was approved in the United States in 2005, and the European Union in 2008, for breast cancer cases where cancer did not respond to other chemotherapy or has relapsed. In 2012, the FDA widened the approved uses to include treatment for NSCLC. In 2013, the FDA approved protein-bound paclitaxel for use in treating advanced pancreatic cancer as a less toxic (although less effective) alternative to FOLFIRINOX. Society and culture
Abraxane is registered on the Australian Register of Therapeutic Goods for the treatment of metastatic carcinoma of the breast after failure of anthracycline therapy. Abraxane is also included on the Schedule of the Australian Pharmaceutical Benefits Scheme although the manufacturer was unable to convince the independent Pharmaceutical Benefits Advisory Committee that the drug warranted a higher price than existing comparator drugs.